EP-1257: Stereotactic ablative radiotherapy for low to intermediate risk prostate cancer. (April 2015) - Sadozye, A.; Dodds, D.; MacLeod, N.; Lamb, C.; Smith, S.; Foster, J.; Devlin, L.; Dufton, A.